NASDAQ:BIAF

bioAffinity Technologies (BIAF) Stock Price, News & Analysis

bioAffinity Technologies logo
$1.70 -0.15 (-7.95%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About bioAffinity Technologies Stock (NASDAQ:BIAF)

Advanced

Key Stats

Today's Range
$1.69
▼
$1.85
50-Day Range
$1.86
▼
$9.43
52-Week Range
$1.69
▼
$80.70
Volume
44,377 shs
Average Volume
1.24 million shs
Market Capitalization
$3.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for lung disease, including lung cancer. Its work centers on applying flow cytometry and other technologies to analyze biological samples and support earlier disease detection.

The company’s lead product, CyPath Lung, is a laboratory-developed test that analyzes sputum samples using proprietary technology. It is intended to help assess lung cancer risk in patients with suspicious pulmonary nodules and is offered through the company’s clinical laboratory subsidiary, Precision Pathology Services.

Based in San Antonio, Texas, bioAffinity Technologies also provides pathology and diagnostic laboratory services through Precision Pathology Services, including testing in areas such as cytopathology and molecular diagnostics. Its operations primarily serve the U.S. market.

AI Generated. May Contain Errors.

bioAffinity Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

BIAF MarketRank™: 
0.49438509997 of 5 stars

bioAffinity Technologies scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    bioAffinity Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    bioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about bioAffinity Technologies' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of bioAffinity Technologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of bioAffinity Technologies is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    bioAffinity Technologies has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.11% of the float of bioAffinity Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    bioAffinity Technologies has a short interest ratio ("days to cover") of 0.48, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in bioAffinity Technologies has recently decreased by 19.80%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    bioAffinity Technologies does not currently pay a dividend.

  • Dividend Growth

    bioAffinity Technologies does not have a long track record of dividend growth.

  • News Sentiment

    bioAffinity Technologies has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for bioAffinity Technologies this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.40% of the stock of bioAffinity Technologies is held by insiders.

  • Percentage Held by Institutions

    1.64% of the stock of bioAffinity Technologies is held by institutions.

  • Read more about bioAffinity Technologies' insider trading history.
Receive BIAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIAF Stock News Headlines

bioAffinity Reports Record October CyPath Lung Test Volume
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
bioAffinity Technologies (BIAF) Set to Post Quarterly Earnings on Wednesday
See More Headlines

BIAF Stock Analysis - Frequently Asked Questions

bioAffinity Technologies' stock was trading at $17.70 at the beginning of 2026. Since then, BIAF shares have decreased by 90.3% and is now trading at $1.7250.

bioAffinity Technologies, Inc. (NASDAQ:BIAF) issued its quarterly earnings data on Friday, November, 6th. The company reported ($5.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($31.50) by $25.61. The company earned $1.07 million during the quarter, compared to analyst estimates of $1.91 million. bioAffinity Technologies had a negative net margin of 278.90% and a negative trailing twelve-month return on equity of 293.44%.

bioAffinity Technologies shares reverse split on the morning of Friday, September 19th 2025.The 1-30 reverse split was announced on Wednesday, September 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

bioAffinity Technologies (BIAF) raised $8 million in an initial public offering (IPO) on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager.

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Bollinger Innovations (BINI), Biostem Technologies (BSEM), Intel (INTC), Micron Technology (MU), NVIDIA (NVDA), Oncolytics Biotech (ONCY) and KeyCorp (KEY).

Company Calendar

Last Earnings
11/06/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:BIAF
CIK
1712762
Fax
N/A
Employees
57
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($44.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.91 million
Net Margins
-278.90%
Pretax Margin
-278.83%
Return on Equity
-293.44%
Return on Assets
-160.36%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.51
Quick Ratio
1.47

Sales & Book Value

Annual Sales
$6.16 million
Price / Sales
0.51
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.15 per share
Price / Book
0.80

Miscellaneous

Outstanding Shares
1,820,000
Free Float
1,776,000
Market Cap
$3.15 million
Optionable
Not Optionable
Beta
-1.04

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:BIAF) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners